Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models.

abstract：:Neurofibromatosis type 2 (NF2) is an autosomal dominant condition caused by pathogenic variants in the NF2 gene. To date, cytotoxic chemotherapy has no established role in the treatment of NF-2. Historical case reports of malignant schwannomas have documented responses to chemotherapies with cyclophosphamide, vincrist...

journal_title：Anti-cancer drugs

authors： Nigro O,Coppola A,Tartaro T,Tuzi A,Vallini I,Pinotti G

更新日期：2020-08-01 00:00:00

abstract：:CHS 828, a pyridyl cyanoguanidine, is a new drug candidate now in phase I/II trials, that has shown promising anticancer activity in experimental tumor models and primary cultures of cancer cells from patients. In this study the fluorometric microculture cytotoxicity assay was used for evaluation of CHS 828 in primary...

journal_title：Anti-cancer drugs

authors： Frost BM,Lönnerholm G,Nygren P,Larsson R,Lindhagen E

更新日期：2002-08-01 00:00:00

abstract：:Imatinib is the standard first-line therapy for metastatic gastrointestinal stromal tumors. It has markedly improved the prognosis and outcome of patients affected by gastrointestinal stromal tumors, especially in the case of exon 11 KIT mutations. Imatinib-associated adverse events are generally mild to moderate; how...

journal_title：Anti-cancer drugs

authors： Saponara M,Gatto L,Di Nunno V,Tabacchi E,Fanti S,Di Scioscio V,Nannini M,Gruppioni E,Altimari A,Fiorentino M,Santini D,Ceccarelli C,Zompatori M,Biasco G,Pantaleo MA

更新日期：2016-04-01 00:00:00

abstract：:Our objective was to determine the maximum tolerated dose (MTD) of paclitaxel when given as a 7 day continuous i.v. infusion, repeated every 3 weeks, and to evaluate the toxicity and the efficacy of such a schedule of administration as a salvage treatment in ovarian cancer patients pretreated and refractory to 3 or 24...

journal_title：Anti-cancer drugs

authors： Soulié P,Trandafir L,Taamma A,Lokiec F,Brain E,Delord JP,Mita A,Vannetzel JM,Cvitkovic E,Misset JL

更新日期：1997-09-01 00:00:00

abstract：:Antimicrobial peptides of the cathelicidin family play a central role in the host defense system. Our group has reported previously that cathelicidin-related or cathelicidin-modified antimicrobial peptides, such as FF/CAP-18, have antiproliferative effects on the squamous cell carcinoma cell line SAS-H1 and colon canc...

journal_title：Anti-cancer drugs

authors： Kuroda K,Fukuda T,Okumura K,Yoneyama H,Isogai H,Savage PB,Isogai E

更新日期：2013-09-01 00:00:00

abstract：:The primary objective was to determine the optimal doses for gemcitabine (prolonged infusion), liposomal doxorubicin (Myocet) and docetaxel as primary (neoadjuvant) chemotherapy for locally advanced breast cancer. Secondary objectives included evaluation of the safety and efficacy of the regimen. Patients (n=19) with ...

journal_title：Anti-cancer drugs

authors： Schmid P,Krocker J,Schulz CO,Michniewicz K,Dieing A,Eggemann H,Heilmann V,Blohmer JU,Sezer O,Elling D,Possinger K

更新日期：2005-01-01 00:00:00

abstract：:Venetoclax is a first-in-class orally available, B-cell lymphoma (BCL)-2 inhibitor indicated for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) harboring the 17p deletion. We used a novel approach for evaluating venetoclax pharmacokinetics using only sparse sampling in 155 patien...

journal_title：Anti-cancer drugs

authors： Salem AH,Dunbar M,Agarwal SK

更新日期：2017-09-01 00:00:00

abstract：:STAT5 is an important transcription factor that is constitutively activated in various types of malignancies, including chronic myelogenous leukemia (CML). Whether the antitumor effects of resveratrol (RES) are linked to its capability to inhibit STAT5 activation in CML cells was investigated. We found that RES inhibi...

journal_title：Anti-cancer drugs

authors： Li Q,Zhang L,Ma L,Bai X,Li X,Zhao M,Sui T

更新日期：2018-08-01 00:00:00

abstract：:Previous in vitro biochemical studies have revealed that the antitumor drug leinamycin causes oxidative DNA damage and DNA alkylation. However, it is still not clear whether the same mechanism(s) of action operate in cultured human tumor cells. Here, we evaluated the effects of leinamycin in the human pancreatic carci...

journal_title：Anti-cancer drugs

authors： Bassett S,Urrabaz R,Sun D

更新日期：2004-08-01 00:00:00

abstract：:Although 5-fluorouracil (5-FU) has been used to treat breast and colorectal cancers for several decades, bolus 5-FU has disappointing efficacy. Prolonged infusion schedules and biomodulation with leucovorin have resulted in improved response rates, but these have not translated into significant improvements in surviva...

journal_title：Anti-cancer drugs

authors： Johnston PG,Kaye S

更新日期：2001-09-01 00:00:00

abstract：:Targeted cancer chemotherapy is a novel approach developed for the specific delivery of anticancer drugs. Tumour targeting can be achieved by combining a chemotherapeutic agent with a targeting moiety that recognizes tumour-specific or highly expressed receptors on cancer cells. We used the gonadotropin-releasing horm...

journal_title：Anti-cancer drugs

authors： Manea M,Tóvári J,Tejeda M,Schulcz A,Kapuvári B,Vincze B,Mezo G

更新日期：2012-01-01 00:00:00

abstract：:Leucine-rich repeat containing G protein-coupled receptor 5 (Lgr5) is a colorectal cancer (CRC) stem cell marker. The role of Lgr5-expressing stem cells in resistance to chemotherapy is controversial. The notion that Lgr5-expressing cells are more chemotherapy resistant is supported by some data; other data do not sup...

journal_title：Anti-cancer drugs

authors： Planutis AK,Holcombe RF,Planoutene MV,Planoutis KS

更新日期：2015-10-01 00:00:00

abstract：:Glassy cell carcinoma (GCC) of the uterine cervix is a highly malignant tumor and has a poor prognosis. As yet, no effective systemic chemotherapy to this tumor has been reported. Here we describe a case of recurrent GCC that responded to paclitaxel and carboplatin combination treatment. The patient, a 32-year-old wom...

journal_title：Anti-cancer drugs

authors： Hirashima Y,Kobayashi H,Nishiguchi T,Miura K,Kanayama N

更新日期：2001-08-01 00:00:00

abstract：:Lung cancer is considered the number one killer among all cancers. Recent observations have altered the treatment paradigm for non-small-cell lung cancer (NSCLC). The discovery of activating mutations in the epidermal growth factor receptor and anaplastic lymphoma kinase positivity has made personalized treatment for ...

journal_title：Anti-cancer drugs

authors： Petrosyan F,Daw H,Haddad A,Spiro T

更新日期：2012-11-01 00:00:00

abstract：:Methoxymorpholinyl doxorubicin (PNU 152243) is a morpholinyl analog possessing a methoxymorpholinyl group at the 3' position of the sugar moiety, which, compared with doxorubicin, appears to be less cardiotoxic and more cytotoxic against multidrug-resistant tumor cells. In this study, we report the anticancer activity...

journal_title：Anti-cancer drugs

authors： Yuan S,Zhang X,Lu L,Xu C,Yang W,Ding J

更新日期：2004-07-01 00:00:00

abstract：:Systemic chemotherapy for patients with a good performance status and advanced non-small cell lung cancer may result in prolonged survival and improved quality of life. However, few single agents have an activity of more than 15% and they have significant toxicity. Cisplatin is widely regarded as the single agent of c...

journal_title：Anti-cancer drugs

authors： Abratt RP

更新日期：1995-12-01 00:00:00

abstract：:Results from our previous phase II study demonstrating high efficacy and low toxicity for a weekly schedule of 5-fluorouracil (5-FU)/leucovorin in intensively pretreated patients with metastatic breast cancer prompted addition of paclitaxel and cisplatin to this regimen for a phase II study of outpatient first-line tr...

journal_title：Anti-cancer drugs

authors： Klaassen U,Wilke H,Weyhofen R,Harstrick A,Eberhardt W,Müller C,Korn M,Hanske M,Diergarten K,Seeber S

更新日期：1998-03-01 00:00:00

abstract：:The anticancer drug candidates 1,3-dibenzyl-4,5-diphenyl-imidazol-2-ylidene gold(I) dimethylamino dithiocarbamate and 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl-1-thiolate derivative exhibited nanomolar in-vitro activity against prostate cancer cells advanced prostate cancer (PC3) and micromolar inhibition of mammalian...

journal_title：Anti-cancer drugs

authors： Walther W,Althagafi D,Curran D,O'Beirne C,Mc Carthy C,Ott I,Basu U,Büttner B,Sterner-Kock A,Müller-Bunz H,Sánchez-Sanz G,Zhu X,Tacke M

更新日期：2020-08-01 00:00:00

abstract：:Large (>6 microm) rigid microparticles (MPs) become passively entrapped within the lungs after intravenous (i.v.) injection making them an attractive and highly efficient alternative to inhalation for pulmonary delivery. In this study, PEGylated 6 microm polystyrene MPs with multiple copies of the norvaline (Nva) alph...

journal_title：Anti-cancer drugs

authors： Chao P,Deshmukh M,Kutscher HL,Gao D,Rajan SS,Hu P,Laskin DL,Stein S,Sinko PJ

更新日期：2010-01-01 00:00:00

abstract：:The anticancer effects of artesunate (ART) have been well documented. However, its potential against skin cancer has not been explored yet. Herein we reported that 60 μmol/l ART effectively inhibited A431 (human epidermoid carcinoma cells) growth but not that of HaCaT (normal human keratinocyte cells). Our results rev...

journal_title：Anti-cancer drugs

authors： Jiang Z,Chai J,Chuang HH,Li S,Wang T,Cheng Y,Chen W,Zhou D

更新日期：2012-07-01 00:00:00

abstract：:There is growing interest in the discovery of bioactive metabolites from endophytes as an alternative source of therapeutics. Identification of their therapeutic targets is essential in understanding the underlying mechanisms and enhancing the resultant therapeutic effects. As such, bioactive compounds produced by end...

journal_title：Anti-cancer drugs

authors： Hazalin NA,Lim SM,Cole AL,Majeed AB,Ramasamy K

更新日期：2013-09-01 00:00:00

abstract：:The goal of our study was to determine whether an apoptosis assay used after short-term drug exposure could predict selective toxicity to cancer cells. To this end we compared the effect of eight anticancer drugs and 10 toxic compounds without known antitumor activity in cultures of human breast cancer cells and norma...

journal_title：Anti-cancer drugs

authors： Frankfurt OS,Krishan A

更新日期：2003-08-01 00:00:00

abstract：:OncoGel is a novel depot formulation of paclitaxel designed for intralesional injection with a sustained paclitaxel delivery over approximately 6 weeks from a single administration. This phase 1 study was designed to characterize the toxicity, pharmacokinetics and preliminary antitumor activity associated with OncoGel...

journal_title：Anti-cancer drugs

authors： Vukelja SJ,Anthony SP,Arseneau JC,Berman BS,Cunningham CC,Nemunaitis JJ,Samlowski WE,Fowers KD

更新日期：2007-03-01 00:00:00

abstract：:Small molecule tyrosine kinase inhibitors are rapidly being integrated into the management of cancer. This is the first report of sorafenib and sunitinib, both small molecule tyrosine kinase inhibitors of vascular endothelial growth factor and platelet-derived growth factor receptors, triggering radiation recall derma...

journal_title：Anti-cancer drugs

authors： Chung C,Dawson LA,Joshua AM,Brade AM

更新日期：2010-02-01 00:00:00

abstract：:Organotypic cultures of human A549 cells were used as a tumor model to investigate sequence effects for combination treatments with adriamycin (ADR) and X-irradiation. Initial drug exposure led to the greatest cytotoxic effect especially when X-rays were delivered 24 h later and this subsequent irradiation did not sig...

journal_title：Anti-cancer drugs

authors： Chevillard S,Vielh P,Campana F,Bastian G,Coppey J

更新日期：1992-04-01 00:00:00

abstract：:The aim of this study was to investigate the effect that recombinant interleukin-2 (rIL-2) (0.16 MUI/injection) had on the pharmacokinetics of imatinib (IM) in plasma. In this study, IM was given orally to mice at a dose of 150 mg/kg once a day for 11 days (from day 1 to 11) either alone or in combination with intrape...

journal_title：Anti-cancer drugs

authors： Hosten B,Abbara C,Cibert M,Petit B,Farinotti R,Gonin P,Bonhomme-Faivre L

更新日期：2010-02-01 00:00:00

abstract：:Macroautophagy (hereafter referred to as autophagy) plays essential roles in cellular and organismal homeostasis. Transcription factor EB (TFEB) is a master regulator of autophagy and lysosome biogenesis. It is not fully understood how the function of TFEB in autophagy pathway is regulated. Here, we show that Rac1 GTP...

journal_title：Anti-cancer drugs

authors： Ma L,Ma Y,Zhang Z,Wang Q,Liu X

更新日期：2019-11-01 00:00:00

abstract：:beta-Lapachone is a naturally occurring quinone obtained from the bark of the lapacho tree (Tabebuia avellanedae) with cancer chemopreventive properties. The objective of the present study was to investigate the effect of beta-lapachone on the cell growth and apoptosis in human colon carcinoma tumor cell line HCT-116....

journal_title：Anti-cancer drugs

authors： Choi BT,Cheong J,Choi YH

更新日期：2003-11-01 00:00:00

abstract：:Leiomyosarcomas represent the most common variant of uterine sarcomas, and are also considered to be the least chemosensitive. To date, adriamycin and ifosfamide are believed to be the most effective drugs for its treatment, in addition to docetaxel and gemcitabine. Recently, the introduction of trabectedin has provid...

journal_title：Anti-cancer drugs

authors： Tavella K,Villanucci A,Vannini L,Lavacchi D,Montelatici S,Amunni G,Mazzei T

更新日期：2017-04-01 00:00:00

abstract：:Tolerability and response rate to weekly combination chemotherapy with trastuzumab and vinorelbine in Japanese women with HER2-overexpressing breast cancer not previously receiving either therapy were assessed. Tumor response was evaluated every 4 weeks and adverse events were graded. A total of 23 patients from six p...

journal_title：Anti-cancer drugs

authors： Tokudome N,Ito Y,Hatake K,Toi M,Sano M,Iwata H,Sato Y,Saeki T,Aogi K,Takashima S

更新日期：2008-08-01 00:00:00